SwiftDx

SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies.

Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist equipment or laboratory facilities.

The company's first commercial product is a rapid mycoplasma contamination detection kit for cell culture applications. Further products in development target HIV, dengue fever, hepatitis C, and prostate cancer.